Maze Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Maze Therapeutics, Inc. (Nasdaq: MAZE) is a clinical-stage biopharmaceutical company focused on translating genetic insights into novel, small-molecule precision medicines. Leveraging its proprietary Compass platform, the company identifies and functionalizes genetic variants to target the biological pathways driving renal, cardiovascular, and metabolic diseases. Maze's pipeline is led by two wholly owned clinical programs: MZE829, a dual-mechanism APOL1 inhibitor for APOL1-mediated kidney disease (AMKD), and MZE782, an oral SLC6A19 inhibitor being developed for chronic kidney disease (CKD) and phenylketonuria (PKU).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing MZE829, an oral, small molecule, dual-mechanism APOL1 inhibitor, for the treatment of APOL1-mediated kidney disease (AMKD). Following positive Phase 2 HORIZON trial topline data showing a 35.6% mean proteinuria reduction at week 12, the company is preparing to advance the candidate into a pivotal trial.
Expected impact: Establishes a potential first-in-class or best-in-class precision medicine for over one million AMKD patients in the United States.
Developing MZE782, an oral small molecule targeting the solute transporter SLC6A19, as a genotype-agnostic therapy for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD).
Expected impact: Provides a novel, oral treatment option to lower plasma phenylalanine in PKU and reduce proteinuria in CKD.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Shionogi acquired exclusive worldwide rights to develop and commercialize MZE001, an investigational oral GYS1 inhibitor for Pompe disease, and related backup programs. This partnership was established in May 2024 after a previous licensing deal with Sanofi was terminated due to FTC antitrust challenges.
Terms: Maze received a $150 million upfront payment. In March 2026, Maze achieved a $20 million milestone payment (received in April 2026) upon the dosing of the first patient in the Phase 2 ESPRIT trial. Maze is eligible for up to $255 million in additional clinical/regulatory milestones, up to $330 million in sales milestones, and tiered royalties ranging from low double-digits to 20% on net sales.
Formed in December 2020, the joint venture Broadwing Bio focuses on developing targeted antibody therapies for ophthalmic diseases by pairing Maze's COMPASS functional genomics platform with Alloy's ATX-Gx mouse platform.
Terms: Co-funded by both companies with options for independent financing and partnering; both companies retain certain participation and commercialization rights.